Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERGENCE: Conversion Surgery for Gastric Cancer With Peritoneal Metastases
NCT07241715Phase 3Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Feb 2026
- Primary completion
- Jan 2034
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric cancer (GC) (2 arms), sponsored by National University Hospital. Primary endpoint: Overall Survival at 36 months. Started Feb 2026; status: active, not recruiting.
02
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07241715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241715.